SLC16A1 and obesity disorder: Beyond contributing to explain the immunosuppressant potential of the MCT1 antagonist AR-C155858 (Murray et al., 2005), our findings support the hypothesis that MCT1 deficiency could affect CD8+ T cells reprogramming during metabolic disturbances such as obesity.